StockNews.com started coverage on shares of LadRx (NASDAQ:CYTR – Get Rating) in a report released on Thursday. The brokerage issued a hold rating on the stock.
LadRx Stock Performance
LadRx has a 52-week low of $0.05 and a 52-week high of $0.86. The company's fifty day moving average is $0.09.
Get
LadRx alerts:
LadRx Company Profile
(Get Rating)
LadRx Corp. is a biopharmaceutical research and development company, which engages in the discovery, research, and clinical development of novel anti-cancer drug candidates. It focuses on developing the Linker Activated Drug Release (LADR) technology platform, a discovery engine to help create a pipeline of anti-cancer molecules that will avoid unacceptable systemic toxicity while delivering highly potent agents directly to the tumor.
Read More
- Get a free copy of the StockNews.com research report on LadRx (CYTR)
- MarketBeat Week in Review – 2/6 – 2/10
- Will Snowflake Have Tough Sledding, Trying To Keep Rally Alive?
- The Bottom Is In For Cloudflare Stock
- 3 Tickers Leading a Meme Stock Revival
- Microsoft-Activision Blizzard Merger: Navigating Risk and Reward
Receive News & Ratings for LadRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LadRx and related companies with MarketBeat.com's FREE daily email newsletter.
StockNews.com started coverage on shares of LadRx (NASDAQ:CYTR – Get Rating) in a report released on Thursday. The brokerage issued a hold rating on the stock.
證券新聞網開始對股票的報導 LaDrX (納斯達克:賽爾特 — 獲得評分) 在星期四發布的報告中。該經紀公司對股票發出了持有評級。
LadRx Stock Performance
LadRx has a 52-week low of $0.05 and a 52-week high of $0.86. The company's fifty day moving average is $0.09.
LADRX 擁有 52 周低點的 0.05 美元和 52 周的高點為 0.86 美元。該公司的五十天移動平均線為 0.09 美元。
Get
LadRx
alerts:
LadRx Company Profile
LadRx Corp. is a biopharmaceutical research and development company, which engages in the discovery, research, and clinical development of novel anti-cancer drug candidates. It focuses on developing the Linker Activated Drug Release (LADR) technology platform, a discovery engine to help create a pipeline of anti-cancer molecules that will avoid unacceptable systemic toxicity while delivering highly potent agents directly to the tumor.
LADRX Corp. 是一家生物製藥研發公司,致力於新型抗癌候選藥物的發現、研究和臨床開發。它專注於開發 Linker 活性藥物釋放(LADR)技術平台,該平台是一種發現引擎,可幫助創建一系列抗癌分子,避免無法接受的全身毒性,同時將高效藥物直接輸送到腫瘤中。
Read More
- Get a free copy of the StockNews.com research report on LadRx (CYTR)
- MarketBeat Week in Review – 2/6 – 2/10
- Will Snowflake Have Tough Sledding, Trying To Keep Rally Alive?
- The Bottom Is In For Cloudflare Stock
- 3 Tickers Leading a Meme Stock Revival
- Microsoft-Activision Blizzard Merger: Navigating Risk and Reward
- 獲取有關 LADRX 研究報告的免費副本
- 市場節拍週的回顧 — 2/6 — 2/10
- 雪花會有艱難的雪橇,試圖保持拉力賽活著嗎?
- 底部是雲耀斑股票
- 3 個帶領模因股票復興的行情
- 微軟動視暴雪合併:導航風險與回報
Receive News & Ratings for LadRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LadRx and related companies with MarketBeat.com's FREE daily email newsletter.
接收有關 LaDrX 每日的新聞和評分 -在下面輸入您的電子郵件地址,以通過 MarketBeat.com 的免費每日電子郵件通訊接收對 LADRX 及相關公司的最新新聞和分析師評級的簡要每日摘要。